McEvoy Joseph P, Lieberman Jeffrey A, Stroup T Scott, Davis Sonia M, Meltzer Herbert Y, Rosenheck Robert A, Swartz Marvin S, Perkins Diana O, Keefe Richard S E, Davis Clarence E, Severe Joanne, Hsiao John K
Clinical Research Service, John Umstead Hospital, 1003 12th St., Bldg. 32, Butner, NC 27705, USA.
Am J Psychiatry. 2006 Apr;163(4):600-10. doi: 10.1176/ajp.2006.163.4.600.
When a schizophrenia patient has an inadequate response to treatment with an antipsychotic drug, it is unclear what other antipsychotic to switch to and when to use clozapine. In this study, the authors compared switching to clozapine with switching to another atypical antipsychotic in patients who had discontinued treatment with a newer atypical antipsychotic in the context of the Clinical Antipsychotic Trials for Interventions Effectiveness (CATIE) investigation.
Ninety-nine patients who discontinued treatment with olanzapine, quetiapine, risperidone, or ziprasidone in phase 1 or 1B of the trials, primarily because of inadequate efficacy, were randomly assigned to open-label treatment with clozapine (N=49) or blinded treatment with another newer atypical antipsychotic not previously received in the trial (olanzapine [N=19], quetiapine [N=15], or risperidone [N=16]).
Time until treatment discontinuation for any reason was significantly longer for clozapine (median=10.5 months) than for quetiapine (median=3.3), or risperidone (median=2.8), but not for olanzapine (median=2.7). Time to discontinuation because of inadequate therapeutic effect was significantly longer for clozapine than for olanzapine, quetiapine, or risperidone. At 3-month assessments, Positive and Negative Syndrome Scale total scores had decreased more in patients treated with clozapine than in patients treated with quetiapine or risperidone but not olanzapine. One patient treated with clozapine developed agranulocytosis, and another developed eosinophilia; both required treatment discontinuation.
For these patients with schizophrenia who prospectively failed to improve with an atypical antipsychotic, clozapine was more effective than switching to another newer atypical antipsychotic. Safety monitoring is necessary to detect and manage clozapine's serious side effects.
当精神分裂症患者对抗精神病药物治疗反应不足时,不清楚该换用哪种其他抗精神病药物以及何时使用氯氮平。在本研究中,作者在临床抗精神病药物干预有效性试验(CATIE)调查的背景下,比较了在停用新型非典型抗精神病药物治疗的患者中换用氯氮平与换用另一种非典型抗精神病药物的情况。
99例在试验第1阶段或1B阶段停用奥氮平、喹硫平、利培酮或齐拉西酮治疗的患者,主要原因是疗效不佳,被随机分配接受氯氮平开放标签治疗(N = 49)或接受试验中未曾使用过的另一种新型非典型抗精神病药物的盲法治疗(奥氮平 [N = 19]、喹硫平 [N = 15] 或利培酮 [N = 16])。
因任何原因停药的时间,氯氮平(中位数 = 10.5个月)显著长于喹硫平(中位数 = 3.3个月)或利培酮(中位数 = 2.8个月),但与奥氮平(中位数 = 2.7个月)无差异。因治疗效果不佳而停药的时间,氯氮平显著长于奥氮平、喹硫平或利培酮。在3个月评估时,接受氯氮平治疗的患者阳性和阴性症状量表总分的下降幅度大于接受喹硫平或利培酮治疗的患者,但与奥氮平治疗的患者无差异。1例接受氯氮平治疗的患者发生粒细胞缺乏症,另1例发生嗜酸性粒细胞增多症;两者均需停药。
对于这些使用非典型抗精神病药物治疗后预期未改善的精神分裂症患者,氯氮平比换用另一种新型非典型抗精神病药物更有效。有必要进行安全监测以发现和处理氯氮平的严重副作用。